In summary, RU486 inhibited GCS-3/dexamethasone combination cytotoxicity and BIM upregulation with no effect on C-MYC expression, indicating that only BIM upregulation is required for the cytotoxicity of the GCS-3/dexamethasone combination against ALL-19 and ALL-54 cells. Here, BCL2L11 is linked to acute lymphoblastic leukemia.